Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Abeona Therapeutics Inc.NASDAQ: ABEO
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $7.32M (cash outflow) rose 207.6% year over year, ahead of the +95.7% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 112.4% of revenue in FY2025.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +207.6% holds above the trailing-twelve-month pace of +95.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 6.54M USD
- Year-over-year change
- +287.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.54M | +287.2% |
| FY2024 | 2024-12-31 | (3.49M) | -271.1% |
| FY2023 | 2023-12-31 | 2.04M | +122.4% |
| FY2022 | 2022-12-31 | (9.11M) | +41.6% |
| FY2021 | 2021-12-31 | (15.59M) | — |
Accounts Payables vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 accounts payables of $1.6M is the 5th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +95.7% is the 4th highest of 10, against a peer median of +12.5%.
- Accounts payables amounts to 11.0% of revenue for ABEO, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.83M | -1.4% | +47.8% | — | |
| LTM Mar 2026 | $2.51M | +12.5% | — | 1116.0% | |
| LTM Mar 2026 | $2.19M | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $2.14M | +172.8% | -54.3% | 0.9% | |
| LTM Mar 2026 | $1.6M | +95.7% | — | 11.0% | |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $254K | +71.6% | — | 0.4% | |
| LTM Mar 2026 | $89K | +101.8% | -20.1% | 0.2% | |
| LTM Mar 2026 | $42K | -102.6% | — | 2.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | +100.0% | — | — |
| Peer median (excluding ABEO) | $0 | +12.5% | -20.1% | 2.1% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Change in Working Capital | (18.26M) | (5.89M) | (1.79M) | (4.38M) | (5.39M) |
| Accounts Receivables | (3M) | 2.81M | (2.04M) | 792K | (5.06M) |
| Inventory | 0 | 0 | 0 | 0 | (5.49M) |
| Accounts Payables | (15.59M) | (9.11M) | 2.04M | (3.49M) | 6.54M |
| Other Working Capital | 324K | 404K | (3.83M) | (1.68M) | (1.37M) |
| Other Non-Cash Items | 24.15M | (5.52M) | 11M | 2.57M | (156.46M) |
| Operating Cash Flow | (65.67M) | (43.48M) | (37.01M) | (56.02M) | (76.33M) |
| Capital Expenditures | (4.15M) | (130K) | (331K) | (2.45M) | (7.98M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.16M) | (78.21M) | (51.64M) | (157.01M) | (206.63M) |
| Sales of Investments | 90.38M | 52.64M | 51.97M | 120.2M | 167.27M |
| Other Investing Activities | 0 | 1.73M | 204K | 18K | 152.37M |
| Investing Cash Flow | 66.06M | (23.96M) | 208K | (39.24M) | 105.03M |
| Debt Repayment | 0 | 0 | 0 | 20M | 0 |
| Common Stock Issued | 24.03M | 46.96M | 37.39M | 85.63M | 26.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 831K | (5K) | (332K) | (1.49M) | (37K) |
| Financing Cash Flow | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.26M | (24.27M) | 256K | 8.88M | 54.74M |
| Free Cash Flow | (69.82M) | (43.61M) | (37.34M) | (58.46M) | (84.3M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.